Sinteza i antimikrobno djelovanje derivata nafto[2,1-b]pirano[2,3-d]pirimidina i pirano[3,2-e][1,2,4]triazolo[1,5-c]pirimidina by FATHY A. EID et al.
Pyrane and fused 4H-pyrane derivatives have attracted a great deal of interest owing
to their antimicrobial activity (1-3), inhibition of influenza, virus sialidases (4), mutage-
nic activity (5), activity as antiviral (6) and antiproliferaction agents (7), sex-pheromones
(8) antitumor (9) and anti-inflammatory agents (10). Moreover, pyrane derivatives are
well known for their antihistaminic activity (11). Also, pyrimidines and fused pyrimi-
dines play an essential role in several biological processes and have a considerable che-
mical and pharmacological importance. In particular, pyrimidine nucleus can be found
in a broad variety of antibacterial and antitumor agents as well as in agrochemical and
veterinary products (12-15).
In continuation of the previous works (16, 17), it seemed interesting to synthesize
new methoxy-4H-naphtho[1',2':5,6]-pyrano[2,3-d]pyrimidine, pyrano[3,2-e][1,2,4[triazo-
lo [2,3-c]pyrimidine and their coumarin-3-yl derivatives by using 2-amino-7-methoxy-4-
-(p-tolyl)-4H-naphtho[2,1-b]pyrane-3-carbonitrile as starting material. These derivatives
might be active against some Gram-positive and Gram-negative organisms.
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Several novel naphtho[2,1-b]pyrano[2,3-d]pyrimidines,
pyrano[3,2-e][1,2,4]triazolo[1,5-c]pyrimidines and their
coumarin-3-yl derivatives were synthesized. Some of
these derivatives exhibited pronounced antimicrobial ac-
tivities.
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EXPERIMENTAL
Melting points were measured using the melting point apparatus (Stuart Scientific
Co., UK) and remained uncorrected. The IR spectra were recorded on a Shimadzu IR 440
spectrophotometer (Shimadzu, Japan) in KBr. 1H NMR and 13C NMR spectra were mea-
sured on a Varian Mercury (300 MHz) spectrometer (Varian, UK), using tetramethylsi-
lane (TMS) as the internal standard and (DMSO-d6) as solvent. Microanalytical data (Ta-
ble I) were obtained from the Microanalytical Unit of the Cairo University (Egypt).
Synthesis of 4H-pyrane derivatives (3a-f). General procedure
A mixture of substituted -cyano-cinnamonitriles (2a-c) (0.01 mol) and/or ethyl-2-
-cyano-3-aryl acrylate (2d-f) (0.01 mol), 6-methoxy-2-naphthol (1) (0.01 mol) and piperi-
dine (0.5 mL) in absolute ethanol (50 mL) was heated until precipitation was completed.
The precipitate was collected by filtration and recrystallized from the suitable solvent.
2-Amino-4-aryl-7-methoxy-4H-naphtho[2,1-b]pyrane-3-carbonnitrile (3a-c) and ethyl
2-amino-4-aryl-7-methoxy-4H-naphtho[2,1-b]pyrane-3-carboxylate (3d-f) afforded colour-
less needles from dioxane and ethanol, respectively.
Synthesis of 2-acetylamino-7-methoxy-4-(p-tolyl)-4H-naphtho[2,1-b]pyrane-
-3-carbonitrile (4a)
A solution of 3a (0.01 mol) in Ac2O (20 mL) was heated under reflux for 30 min. The
solid product formed was filtered off and washed with cold EtOH to give 4a as pale yel-
low crystals (from ethanol).
Synthesis of 2-benzoylamino-7-methoxy-4-(p-tolyl)-4H-naphtho[2,1-b]-
pyrane-3-carbonitrile (4b)
A solution of 3a (0.01 mol) in benzoyl chloride (20 mL) was heated under reflux for
30 min. The excess of benzoyl chloride was removed under reduced pressure and the
residue was poured into water. The precipitate was collected by filtration, washed with
carbon tetrachloride (10 mL) to remove the formed benzoic acid and the residue was
dried to give 4b as colourless crystals from DMF.
Synthesis of 10,11-dihydro-3-methoxy-9-methyl-12-(p-tolyl)-12H-naphtho-
[2,1-b]pyrano[2,3-d]pyrimidine-11-one (5a)
Method A. – A solution of 3a (0.01 mol) in Ac2O (20 mL) was heated under reflux for
6 h. The precipitate was filtered off, washed with cold EtOH to give 5a as colourless
crystals from DMF.
Method B. – Gaseous dry HCl was bubbled through the mixture of 3b (0.01 mol) and
CH3CN (30 mL) for 4-6 h. The reaction mixture was poured into ice water and alkalized
with 10% aqueous ammonium hydroxide to give 5a.
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Synthesis of 10,11-dihydro-3-methoxy-9-phenyl-12-(p-tolyl)-12H-naphtho[2,1-b]-
pyrano[2,3-d]pyrimidine-11-one (5b)
A solution of 3a (0.01 mol) in benzoyl chloride (20 mL) was heated under reflux for
6 h. The excess of benzoyl chloride was removed under reduced pressure and the resi-
due was poured into cold water. The precipitate was collected by filtration, washed with
carbon tetrachloride (10 mL) to remove the formed benzoic acid and the residue was
dried to give 5b as colourless crystals from DMF.
Synthesis of 2-ethoxymethyleneamino-7-methoxy-4-(p-tolyl)-4H-naphtho-
[2,1-b]pyrane-3-carbonitrile (6)
A mixture of 3a (0.01 mol) and triethyl orthoformate (2 mL) in acetic anhydride (10
mL) was refluxed for 2 h. After cooling, the precipitated product was filtered off and
washed several times with cold ethanol to give 6 as colourless crystals from benzene.
Synthesis of pyranopyrimidine derivatives (7a,b). General procedure
Amixture of 6 (0.01 mol), hydrazine hydrate (5 mL, 99%) or methylamine (0.01 mol)
in absolute ethanol (50 mL) was stirred for 1 h at room temperature to give 7a,b. 10-Ami-
no-10,11-dihydro-11-imino-3-methoxy-12-(p-tolyl)-12H-naphtho[2,1-b]pyrano[2,3-d]py-
rimidine (7a) and 10,11-dihydro-11-imino-3-methoxy-10-methyl-12-(p-tolyl)-12H-naphtho-
-[2,1-b]pyrano[2,3-d]pyrimidine (7b) were obtained as colourless crystals from dioxane.
Synthesis of 7-methoxy-2-(N,N-dimethylaminomethylene)-4-
(p-tolyl)-4H-naphtho[2,1-b]pyrane-3-carbonitrile (8)
A mixture of 6 (0.01 mol) and dimethylamine (5 mL) in ethanol was stirred for 1 h.




H2S was bubbled through a solution of 6 (0.01 mol) in absolute ethanol (50 mL) at
room temperature for 1 h. The reaction mixture was stirred for an additional hour to
give 9 as yellow crystals from dioxane.
Synthesis of 11-amino-3-methoxy-12-(p-tolyl)-12H-naphtho-
[2,1-b]pyrano[2,3-d]pyrimidine (10)
Method A. – Gaseous NH3 was bubbled through 6 (0.01 mol) in methanol for 1 h.
The solid formed was collected to give 10 as colourless needles from benzene.
Method B. – A solution of 3a (0.01 mol) in formamide (20 mL) was heated under re-
flux for 6 h to give 10.
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Synthesis of pyranotriazolopyrimidine derivatives (11a-e). General procedure
A mixture of 7a (3.72 g, 0.01 mol), triethyl orthoformate, acetyl chloride or benzoyl
chloride (0.01 mol) in dry benzene (20 mL) was refluxed for 3 h to give 11a-c, while a
mixture of 7a (3.72 g, 0.01 mol) with ethyl cyanoacetate or diethyl oxalate (0.01 mol) in





[1,2,4]triazolo[1,5-c]pyrimidine-2-ethanenitrile (11d) and ethyl 11-methoxy-14-(p-tolyl)-14H-
-naphtho[2,1-b]pyrano[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine-2-carboxylate (11e) were ob-
tained as colourless crystals from dioxane.
Synthesis of 10-benzalamino-10,11-dihydro-11-imino-3-methoxy-12-
(p-tolyl)-12H-naphtho[2,1-b]pyrano[2,3-d]pyrimidine (12)
Amixture of 7a (3.72 g, 0.01 mol), benzaldehyde (0.01 mol), piperidine (0.5 mL) and
dioxane (30 mL) was refluxed for 6 h. The precipitate was filtered off and washed seve-
ral times with cold ethanol to give 12 as colourless crystals from dioxane.
Synthesis of ethyl 14-(p-tolyl)-11-methoxy-2-oxo-2H,3H,14H-naphtho[2,1-b]-
pyrano[2,3-e][1,2,4]triazolo[1,5-c]pyrimidine-3-carboxylate (13)
A mixture of 7a (0.01 mol) and ethyl chloroformate (0.02 mol) in dry benzene (30
mL) was refluxed for 3 h to give 13 as colourless crystals from dioxane.
Synthesis of 2-(coumarin-3-yl)-11-methoxy-14-(p-tolyl)-14H-naphtho[2,1-b]-
pyrano[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine (14a)
A mixture of 11d (0.01 mol), salicylaldehyde (0.01 mol) and dioxane (30 mL) was
refluxed for 3 h. The precipitate was filtered off and washed several times with cold eth-
anol to give 14a as colourless crystals from dioxane.
Synthesis of 2-(benzo-5:6-coumarin-3-yl)-11-methoxy-14-(p-tolyl)-14H-naphtho-
[2,1-b]pyrano[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine (14b)
A mixture of 11d (0.01 mol), 2-hydroxynaphthaldehyde (0.01 mol) and dioxane (30
mL) was refluxed for 3 h. The precipitate was filtered off and washed several times with
cold ethanol to give 14b as colourless crystals from dioxane.
Structures 3-14 were established by elemental analysis, IR, 1H NMR and 13C NMR
spectral data (Tables I and II).
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Table II. Spectral data of the prepared compounds
IR (, cm-1) 1H NMR/13C NMR (, ppm) (DMSO-d6)
3a
3433, 3332 (NH2), 3014,
2964, 2924, 2849 (stretch-
ing CH), 2211 (CN), 1690
(C=C)
2.18 (s, 3H, CH3), 3.80 (s, 3H, OCH3), 5.20 (s, 1H, pyrane CH),
6.93 (br, 2H, NH2, exchangeable), 7.04-7.83 (m, 9H, Ar-H)
20.9 (CH3), 27.7 (C-4), 56.0 (OCH3), 59.2 (C-3), 105.8 (C-7),
117.2 (CN), 118.7 (C-5), 118.9 (C-9), 123.7 (C-10), 126.8 (C-6),
128.3 (Ar), 129.7 (Ar), 131.1 (C-6a), 136.5 (Ar), 143.7 (Ar), 146.2
(C-4), 157.2 (C-8), 160.5 (C-3)
3b
3403, 3322 (NH2), 3058,
2965, 2926 (stretching CH)
2195 (CN), 1660 (C=C)
3.33 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 5.20 (s, 1H, pyrane
CH), 6.82 (br, 2H, NH2 exchangeable), 6.82-7.82 (m, 9H, Ar-H)
3c
3446, 3335 (NH2), 3017,
2924, 2849 (stretching CH),
2211 (CN), 1690 (C=C)
3.80 (s, 3H, OCH3), 5.25 (s, 1H, pyrane CH), 6.94 (br, 2H, NH2,
exchangeable), 7.16-7.81 (m, 10H, Ar-H)
3d
3434, 3304 (NH2), 2992,
2920, 2832 (stretching
CH), 1675 (CO)
1.39 (t, 3H, CH3, J = 7.1Hz), 2.16 (s, 3H, CH3), 3.80 (s, 3H,
OCH3), 4.23 (q, 2H, CH2, J = 7.1Hz), 5.30 (s, 1H, pyrane CH),
6.30 (br, 2H, NH2, exchangeable), 6.99-7.88 (m, 9H, Ar-H)
3e
3425, 3312 (NH2), 2921,
2865 (stretching CH),
1672 (CO)
1.36 (t, 3H, CH3, J = 7.1Hz), 3.72 (s, 3H, OCH3), 3.81 (s, 3H,
OCH3), 4.25 (q, 2H, CH2, J = 7.1Hz), 5.53 (s, 1H, pyrane CH),
6.31 (br, 2H, NH2, exchangeable), 7.01-7.91 (m, 9H, Ar-H)
3f
3410, 3311 (NH2), 2990,
2930, 2872 (stretching
CH), 1665 (CO)
1.36 (t, 3H, CH3, J = 7.1Hz), 3.80 (s, 3H, OCH3), 4.25 (q, 2H,
CH2, J = 7.1Hz), 5.53 (s, 1H, pyrane CH), 6.30 (br, 2H, NH2,
exchangeable), 6.99-7.88 (m, 10H, Ar-H)
4a
3444 (NH), 3026, 3007,
2957, 2923 (stretching
CH), 2216 (CN), 1733 (CO)
2.16 (s, 3H, CH3), 2.41 (s, 3H, COCH3), 3.76 (s, 3H, OCH3),
5.78 (s, 1H, pyrane CH), 7.10-7.91 (m, 9H, Ar-H), 10.59 (br,
1H, NH, exchangeable)
4b
3353 (NH), 3041, 2957,
2923 (stretching CH), 2218
(CN), 1728 (CO)
2.16 (s, 3H, CH3), 3.83 (s, 3H, OCH3), 5.78 (s, 1H, pyrane CH),
7.12-7.97 (m, 14H, Ar-H), 11.10 (br, 1H, NH, exchangeable)
5a
3432 (NH), 3001, 2981, 2920
(stretching CH), 1660 (CO)
2.30 (s, 3H, CH3), 2.20 (s, 3H, CH3), 3.79 (s, 3H, O CH3), 5.74
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5b
3320 (NH), 3001, 2960
(stretching CH) 1665 (CO)
2.28 (s, 3H, CH3), 3.80 (s, 3H, OCH3), 5.76 (s, 1H, pyrane CH),
7.35-8.12 (m, 15H, Ar-H + NH)
6
3040, 2985, 2951 (stretch-
ing CH), 2205 (CN), 1650
(C=N)
1.41 (t, 3H, CH3, J = 7.1Hz), 2.28 (s, 3H, CH3), 3.88 (s, 3H,
CH3), 4.45 (q, 2H, CH2, J = 7.1Hz), 5.28 (s, 1H, pyrane CH),
7.09-7.18 (m, 9H, Ar-H), 8.42 (s, 1H, N=CH)
7a
3314, 3265 (NH2), 3200
(NH), 2948, 2899 (stretch-
ing CH), 1646 (C=N)
2.13 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 5.68 (s, 1H, pyrane CH),
5.81 (br, 2H, NH2, exchangeable), 6.90-7.81 (m, 10H, Ar-H
+NH), 8.16 (s, 1H, pyrimidine)
7b
3375 (NH), 3002, 2981,
2829 (stretching CH), 1620
(C=N)
2.13 (s, 3H, CH3), 3.35 (s, 3H, NCH3), 3.81 (s, 3H, OCH3), 6.02
(s, 1H, pyrane CH), 7.01-7.92 (m, 9H, Ar-H), 8.27 (s, 1H, py-
rimidine CH)
8
2984, 2925 (stretching CH),
2205 (CN), 1621 (C=N)
2.12 (s, 3H, CH3), 3.11 (s, 3H, NCH3), 3.4 (s, 3H, NCH3), 5.64
(s, 1H, pyrane CH), 7.01-7.98 (m, 9H, Ar-H), 8.52 (s, 1H,
N=CH)
9
3325 (NH), 2948, 2899
(stretching CH), 1646
(C=N), 1043 (C=S)
2.13 (s, 3H, CH3), 3.83 (s, 3H, OCH3), 6.08 (s, 1H, pyrane CH),
6.9-7.88 (m, 10H, Ar-H+NH), 8.31 (s, 1H, pyrimidine CH)
10
3477, 3371 (NH2), 3001,
2993, 2925 (stretching CH),
1614 (C=N), 1582 (C=C)
2.18 (s, 3H, CH3), 3.80 (s, 3H, OCH3), 4.86 (br, 2H, NH2, ex-
changeable), 5.68 (s, 1H, pyrane CH), 6.88-7.91 (m, 9H, Ar-H),
8.30 (s, 1H, pyrimidine CH)
11a
2984, 2925 (stretching CH),
1632 (C=C)
2.11 (s, 3H, CH3), 3.84 (s, 3H, OCH3), 6.24 (s, 1H, pyrane CH),
6.98-7.91 (m, 9H, Ar-H), 8.63 (s, 1H, pyrimidine CH), 9.64 (s,
1H, 2-H)
11b
3076, 2952, 2928 (stretch-
ing CH), 1633 (C=C)
2.12 (s, 3H, CH3), 2.50 (s, 3H, CH3), 3.83 (s, 3H, OCH3), 6.21
(s, 1H, pyrane CH), 6.99-7.99 (m, 9H, Ar-H), 9.51 (s, 1H, py-
rimidine CH)
11c
3064, 2961, 2929 (stretch-
ing CH), 1633 (C=C)
2.14 (s, 3H, CH3), 3.84 (s, 3H, OCH3), 6.41 (s, 1H, pyrane CH),
7.03-7.91 (m, 14H, Ar-H), 8.70 (s, 1H, pyrimidine CH)
11d
2995, 2936 (stretching CH),
2255 (CN), 1633 (C=C)
2.12 (s, 3H, CH3), 3.80 (s, 3H, OCH3), 4.50 (s, 2H, CH2), 6.23
(s, 1H, pyrane CH), 6.99-7.94 (m, 9H, Ar-H), 9.64 (s, 1H, py-
rimidine CH)
11e
3076, 2952 (stretching CH),
1633 (C=C)
1.38 (t, 3H, CH3, J = 7.1Hz), 2.16 (s, 3H, CH3), 3.78 (s, 3H,
OCH3), 4.44 (q, 2H, CH2, J = 7.1Hz), 6.24 (s, 1H, pyrane CH),
6.99-7.92 (m, 9H, Ar-H), 9.73 (s, 1H, pyrimidine CH)
12
3261 (NH), 3067, 2981,
2924 (stretching CH), 1652
(C=N)
2.15 (s, 3H, CH3), 3.84 (s, 3H, OCH3), 6.31 (s, 1H, pyrane CH),
7.01-8.01 (m, 14H, Ar-H+NH), 8.27 (s, 1H, N=CH), 9.64 (s, 1H,
pyrimidine CH)
13
3025, 2987, 2924 (stretch-
ing CH) 1716 (CO)
1.39 (t, 3H, CH3, J = 7.1Hz), 2.28 (s, 3H, CH3), 3.81 (s, 3H,
OCH3), 4.43 (q, 2H, CH2, J = 7.1Hz), 6.28 (s, 1H, pyrane CH),
6.80-7.81 (m, 9H, Ar-H), 8.5 (s, 1H, pyrimidine CH)
14a
3074, 2931 (stretching CH),
1744 (CO) and 1622 (C=C)
2.12 (s, 3H, CH3), 3.84 (s, 3H, OCH3), 6.28 (s, 1H, pyrane CH),
7.01-7.95 (m, 14H, Ar-H+NH), 9.05 (s, 1H, 4-H), 9.69 (s, 1H,
pyrimidine CH)
14b 3026, 2931 (stretching CH),
1748 (CO) and 1635 (C=C)
2.16 (s, 3H, CH3), 3.76 (s, 3H, OCH3), 6.32 (s, 1H, pyrane CH),




The new synthesized compounds were screened for their antimicrobial activity in
vitro against three species of Gram-positive bacteria, Staphylococcus aureus (NCTC-7447),
Bacillus cereus (ATCC-14579) and Bacillus subtilis (NCTC-10400) and three Gram-negative
bacteria, Escherichia coli (NCTC-10410), Serratia marcescens (IMRU-70) and Proteus mira-
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Table III. Antimicrobial activity of the new compounds
Compd.
No.a



















3a 14 12 13 12 10 14
3b 16 14 15 14 13 15
3c 13 11 12 10 11 12
3d 12 10 10 11 13 11
3e 14 13 11 14 12 10
3f 10 11 10 12 11 12
4a 10 12 – 11 – 10
4b 12 10 – 14 13 15
5a 21 20 22 23 21 19
5b 23 22 20 21 23 20
6 10 12 – 12 – 11
7a 17 18 19 23 20 21
7b 14 15 16 25 23 20
8 11 10 – 10 12 13
9 18 17 20 13 14 25
10 17 19 19 24 23 20
11a 22 21 20 23 24 20
11b 24 25 22 21 22 22
11c 22 23 24 25 26 20
11d 23 20 26 24 24 22
11e 21 22 25 26 20 20
12 20 18 21 20 21 17
13 22 20 23 22 24 18
14a 26 25 24 23 25 22
14b 27 28 26 24 28 24
22 22 20 22 22 18
a c = 1 mg mL–1 of new compounds in DMF.
Ampicillin
(25 g mL–1)
bilis (NTCC-289), using the paper disc diffusion method (18). Filter paper discs manufac-
tured by Bristol-Myers Squibb (Egypt) were used.
The tested compounds were dissolved in N,N-dimethylformamide (DMF) to get a
solution of 1 mg mL-1. The inhibition zones were measured in millimeters at the end of
an incubation period of 48 h at 28 °C. DMF showed no inhibition zones. The ampicillin
standard was used as a reference.
RESULTS AND DISCUSSION
Condensation of 6-methoxy-2-naphthol (1) with substituted -cyano-cinnamonitriles
(2a-c) and/or ethyl-2-cyano-3-aryl acrylate (2d-f) afforded the corresponding 2-amino-
-4-aryl-7-methoxy-4H-naphtho[2,1-b]pyrane-3-carbonitrile (3a-c) and ethyl-3-carboxylate
(3d-f), respectively (19, 20). Treatment of 3a with Ac2O gave two products dependening
on the reaction time; one product was identified as 2-acetylamino-7-methoxy-4-(p-to-
lyl)-4H-naphtho[2,1-b]pyrane-3-carbonitrile (4a) (30 min), while the other was identified
as 10,11-dihydro-3-methoxy-9-methyl-12-(p-tolyl)-12H-naphtho[2,1-b]pyrano[2,3-d]pyri-
midine-11-one (5a, 6 h). Similarly, the reaction of 3a with benzoyl chloride gave the cor-
responding 2-benzoylamino-4H-naphthopyran-3-carbonitrile (4b) and 9-phenyl pyrimi-
dine derivative (5b). Structure 4a was established on the basis of IR, which showed the
presence of CN at 2216 cm-1 and CO of the acetyl group at 1732 cm-1 and for 5a the ab-
sence of CN and the presence of amide carbonyl at 1660 cm-1. 1H NMR showed a signal
for COCH3 and for 5a a signal for 9-CH3. Unequivocal support for structure 5 was ob-
21
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a R = CH3
b R = C6H5
a Ar = X = CN
b Ar = X = CN
c Ar = C H6 5 X = CN
d Ar = X = CO Et2
e Ar = OMe X = CO Et2
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a R = H
b R = CH3
c R = C6H5
d R = CH2CN














tained by the independent synthesis of 5a by the reaction of 3d with CH3CN in the pres-
ence of dry HCl gas (21) (Scheme 1).
Reaction of 3a with triethyl orthoformate gave the corresponding 2-ethoxymethy-
leneamino derivative 6. Hydrazinolysis of 6 in ethanol at room temperature yielded 10-
-amino-10,11-dihydro-11-imino-3-methoxy-12-(p-tolyl)-12H-naphtho[2,1-b]pyrano[2,3-d]pyri-
midine (7a). Aminolysis of 6 with methylamine gave the corresponding 10-methyl-pyra-
nopyrimidine derivative 7b, and with dimethylamine it gave 2-N,N-dimethylaminome-
thylene derivative 8. Ammonolysis of 6 gave 11-amino-3-methoxy-12-(p-tolyl)-12H-naphtho-
[2,1-b]pyrano[2,3-d]pyrimidine 10. Also, the structure of 10 was established on the basis
of IR, which showed the absence of CN and showed signals due to –CH pyrimidine.
Also, the structure of compound 10 was established by an independent synthesis from
3a and formamide (m.p. and mixed m.p.) (Scheme 2). Condensation of 6 with H2S yield-
ed a product that was identified as 10,11-dihydro-3-methoxy-12-(p-tolyl)-12H-naphtho-
[2,1-b]pyrano[2,3-d]pyrimidine-11-thione (9). Treatment of 7a with acetyl and/or ben-
zoyl chloride gave the corresponding 11-methoxy-2-methyl/phenyl-14-(p-tolyl)-14H-naph-
tho[2,1-b]pyrano[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine (11b,c), while cyclocondensation of
7a with ethyl cyanoacetate or diethyl oxalate gave the corresponding 2-cyanomethyl and
2-ethoxycarbonyl derivatives (11d,e). Also, 7a reacted with triethyl orthoformate to af-
ford the corresponding [1,2,4]triazolo[1,5-c]pyrimidine derivative (11a), while the reac-
tion of 7a with benzaldehyde gave 10-benzalamino-10,11dihydro-11-imino-3-methoxy-12-
-(p-tolyl)12H-naphtho[2,1-b]pyrano[2,3-d]pyrimidine (12) instead of the expected triazolo-
pyrimidine derivative (11c). Treatment of 7a with two moles of ethyl chloroformate in
dry benzene afforded 1:2 adduct 13 (Scheme 2). Formation of 13 was assumed to pro-
ceed via bis(ethoxycarbonyl) derivative A as intermediate, which cyclized into 13 with
elimination of ethanol (Scheme 2).
On the other hand, when 2-cyanomethylderivative 11d was subjected to the reaction
with phenolic aldehydes, a condensation reaction afforded new pyrano[3,2-e][1,2,4]triazo-
lo[1,5-c]pyrimidine derivatives (14a,b) containing the coumarin moiety (Scheme 3).
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Scheme 3
The present study revealed that substitution at the 2-position of pyrano[3,2-e][1,2,4]-
triazolo[1,5-c]pyrimidine with coumarin-3-yl and/or benzocoumarin-3-yl moieties (com-
pounds 14a,b) caused a pronounced increase in their activities.
It was found that compounds 14a,b possess a pronounced antimicrobial activity
against all tested microorganisms, namely, markedly stronger antimicrobial activity against
both Gram-positive and Gram-negative bacteria than ampicillin. Compounds 5b and
11b,d exhibited stronger activities than ampicillin also towards Staphylococcus aureus,
compounds 11b,c towards Bacillus cereus, compounds 11b-e and 13 posses pronounced
activities towards Bacillus subtilis. Compounds 7b, 10 and 11c-e exhibited pronounced
activities against Serratia marcescens and compounds 11a,c,d and 13 demonstrated inter-
esting activities against Proteus mirabilis. Also, compounds 5a,b, 7a,b, 9, 10, 11a-e and 13
exhibited pronounced activities towards Escherichia coli. Compounds 11a,c and 13 exhib-
ited equal activities as ampicillin towards Staphylococcus aureus, compounds 5b and 11e
the same activities towards Bacillus cereus, compounds 5b, 9 and 11a also the same effect
against Bacillus subtilis. Compound 13 showed the same effect towards Serratia marces-
cens and Escherichia coli, while compound 11b similar activities towards Proteus mirabilis
compared with ampicillin.
In general as far as Gram negative bacteria are concerned compounds 5a,b, 7a,b, 10,
11a,c-e, 13, 14a,b were found more efficient than ampicillin. The same applies to com-
pounds 11b,c,d, 13, 14a,b in the case of Gram positive bacteria.
The remaining compounds differed in their ability to inhibit the growth of microor-
ganisms in dependence on their chemical structure and are all less effective than ampi-
cillin.
CONCLUSIONS
Evaluation of new compounds established that 5a,b, 11a-e, 13 and 14a,b showed
improved antimicrobial activity compared to ampicillin, while compounds 3a-f, 4a,b, 6
and 8 were either inactive or weakly active against the tested microorganisms. We at-
tempted to increase antimicrobial activities by fusing the triazolopyrimidine nucleus
with the pyrane ring. The most active compounds were in which the pyranotriazolopy-
rimidine nucleus was substituted with the coumarin nucleus (compounds 14a,b).
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S A @ E T A K
Sinteza i antimikrobno djelovanje derivata nafto[2,1-b]pirano[2,3-d]pirimidina i
pirano[3,2-e][1,2,4]triazolo[1,5-c]pirimidina
FATHY A. EID, ASHRAF H. F. ABD EL-WAHAB, GAMEEL A. M. EL-HAG ALI i MOUSTAFA M. KHAFAGY
Sintetizirano je nekoliko novih nafto[2,1-b]pirano[2,3-d]pirimidina, pirano[3,2-e][1,2,4]-
triazolo[1,5-c]pirimidina i njihovih kumarin-3-il derivata. Neki od njih imaju izra`eno
antimikrobno djelovanje.
Klju~ne rije~i: derivati piranopirimidina, derivati piranotriazolopirimidina, derivati kumarin-3-il-pi-
ranotriazolopirimidina, antibakterijsko djelovanje
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